for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis India Limited

NOIN.BO

Latest Trade

690.40INR

Change

10.35(+1.52%)

Volume

17,645

Today's Range

670.30

 - 

694.80

52 Week Range

558.00

 - 

780.00

As of on the Bombay Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
680.05
Open
687.05
Volume
17,645
3M AVG Volume
0.28
Today's High
694.80
Today's Low
670.30
52 Week High
780.00
52 Week Low
558.00
Shares Out (MIL)
24.68
Market Cap (MIL)
16,844.06
Forward P/E
--
Dividend (Yield %)
1.47

Next Event

Q3 2020 Novartis India Ltd Earnings Release

Latest Developments

More

Novartis India Posts Sept Qtr Loss

Novartis India June-Qtr Profit Drops

Novartis India March-qtr Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis India Limited

Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods. The Company focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. The Pharmaceuticals segment includes a portfolio of prescription medicines, which are provided to patients through healthcare professionals. Its Pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences. The pharmaceuticals division is engaged in the development and commercialization in oncology, primary care and specialty medicines. The Generics segment comprises retail generics products. The business unit primarily focuses on the therapeutic segments, such as anti-tuberculosis (TB), anti-dysfunctional uterine bleeding (DUB (Gynecology)), antihistamines, antibiotics, anti-ulcerants, anti-diabetes and cardiovascular. The Company's geographical segments include India and Other Countries.

Industry

Biotechnology & Drugs

Contact Info

3Rd Floor, Royal Insurance, Bldg

14 J Tata Road

Churchgate

+91.22.24958400

https://www.novartis.in/

Executive Leadership

Christopher Snook

Non-Executive Chairman of the Board

Sanjay Murdeshwar

Vice Chairman of the Board, Managing Director

Monaz Noble

Chief Financial Officer, Additional Whole Time Director

Trivikram Guda

Compliance Officer, Company Secretary

V. A. Kumar

Key Management Personnel

Key Stats

Price To Earnings (TTM)
50.34
Price To Sales (TTM)
3.56
Price To Book (MRQ)
2.32
Price To Cash Flow (TTM)
40.39
Total Debt To Equity (MRQ)
9.22
LT Debt To Equity (MRQ)
7.83
Return on Investment (TTM)
4.21
Return on Equity (TTM)
3.17

Latest News

Latest News

BRIEF-Novartis India Gets 1.88 Bln Rupees ‍Refund w.r.t Income Tax Appellate Tribunal Order For FY 1994-95​

* GETS REFUND OF 1.88 BILLION RUPEES ON ACCOUNT OF FAVOURABLE ORDER OF INCOME TAX APPELLATE TRIBUNAL FOR FY 1994-95

BRIEF-Novartis India Dec Qtr Profit Rises

* DEC QUARTER PROFIT 187.4 MILLION RUPEES VERSUS PROFIT 130.3 MILLION RUPEES YEAR AGO

BRIEF-Novartis India Sept-qtr profit rises

* Sept quarter profit 261.2 mlnrupees versus profit of 222.1 million rupees last year

BRIEF-Novartis India approves share buyback worth up to 2.31 bln rupees

* Says approved proposal for share buyback worth up to 2.31 billion rupees Source text: http://www.bseindia.com/xml-data/corpfiling/AttachLive/27db088d-e614-4349-ad93-69edfcc5e32f.pdf Further company coverage:

BRIEF-Novartis India ‍to consider share buyback proposal

* Says to consider a proposal for buyback of company's equity shares Source text: http://bit.ly/2hhCOfg Further company coverage:

BRIEF-Novartis India June-qtr profit down 63 pct

* June quarter profit 70.3 million rupees versus profit of 190.7 million rupees last year

BRIEF-Novartis India Dec-qtr profit tanks

* Novartis india ltd - dec quarter net profit 130.3 million rupees

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up